Companies › TCR2 Therapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Nov 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| gavo-cel (TC-210) Autologous T cells expressing single-domain antibody against mesothelin fused to CD3-epsil | – | Phase 1 | Mesothelioma | Nov 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03907852 | gavo-cel (TC-210) | Phase 1 | Mesothelioma | Oncology | Nov 2028 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.